Clinical Trial Update: A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 study of ION251 in patients with relapsed or refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• ION251

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Relapsed Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Status: COMPLETED